Compare CCB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | GERN |
|---|---|---|
| Founded | 1997 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2018 | 1996 |
| Metric | CCB | GERN |
|---|---|---|
| Price | $50.01 | $1.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $126.67 | $2.17 |
| AVG Volume (30 Days) | 197.5K | ★ 9.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | $96.61 | $26.91 |
| Revenue Next Year | $22.66 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.61 | $1.04 |
| 52 Week High | $120.05 | $2.01 |
| Indicator | CCB | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 51.20 |
| Support Level | $45.24 | $1.46 |
| Resistance Level | $53.02 | $1.64 |
| Average True Range (ATR) | 1.99 | 0.07 |
| MACD | 1.09 | -0.01 |
| Stochastic Oscillator | 53.04 | 41.67 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.